Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Julia Kollewe

Novo Nordisk shares climb after positive anti-obesity pill results

Novo Nordisk head office
Novo Nordisk, based in Copenhagen, Denmark, is racing to trump its US rival Eli Lilly. Photograph: Tom Little/Reuters

The value of the drugmaker Novo Nordisk jumped by about £9bn on Thursday after research showed that taking its new anti-obesity pill can result in almost as much weight loss as its Wegovy jab.

The Danish company is racing against its US rival Eli Lilly to get a tablet treatment to market. Shares in Novo Nordisk climbed by more than 6% on hopes that it can claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.